Paula Finnegan

Paula Finnegan

Auto-generated profile, based on publicly available information

Paula Finnegan

Department of Dermatology, South Infirmary Victoria University Hospital, Cork, Ireland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Clinical and Experimental Dermatology
Verified
Journal Article
Open access
PDF file
PFPaula Finnegan
Paula Finnegan
MMMichelle Murphy
Michelle Murphy
COCathal O’cOnnor
Cathal O’cOnnor
Misinformation in healthcare is at crisis level worldwide, with the internet as primary source of prevarication. Topical corticosteroids (TCS) are a safe and effective treatment used in multiple dermatological conditions. Nonadherence to prescribed TCS can be due to phobia secondary to misinformation. TCS phobia is a complex multifaceted phenomenon that exploits patients with skin disease, creates cognitive dissonance and can obstruct successful treatment. This study aimed to examine the content of TCS-related misinformation available online. A formal review of PubMed was performed using the terms ‘topical corticosteroids’ AND ‘misinformation’ OR ‘disinformation’ OR ‘conspiracy theory, along with an informal Google search using combinations of these terms and further targeted searches on social media applications including Facebook™, Twitter™, Instagram™ and TikTok™. ‘Topical steroid withdrawal’, ‘red skin syndrome’ or ‘TCS addiction’ is a particularly prevalent myth currently being propagated on social media, with most content suggesting that eczema is due to a ‘leaky gut’ or food intolerance and not to skin inflammation. The risks of potential adverse effects such as skin thinning and stunted growth/development are often exaggerated. Multiple websites promoting misinformation were frequently endorsed by companies advertising consultations or testing to identify ‘underlying causes’, or ‘natural’ products as alternative treatments, including ‘herbal’ remedies, which can contain significant quantities of corticosteroids or other potent ingredients. The dermatology community should be vigilant of the type of TCS-related misinformation online and be active in attempts to counteract it with evidence-based advice.

27 July 2022 in Immunotherapy
Verified
Journal Article
Closed access
COCathal O’cOnnor
Cathal O’cOnnor
PFPaula Finnegan
Paula Finnegan
DPDerek G Power
Derek G Power
MBMary Bennett
Mary Bennett
JBJohn F Bourke
John F Bourke
A 66-year-old woman receiving pembrolizumab for metastatic melanoma presented with tender red nodules on her shins and forearms. Biopsy was consistent with erythema nodosum (EN). The eruption respo... Plain language summary Pembrolizumab (trade name Keytruda®) is a type of immune therapy that stimulates the body's immune system to fight cancer cells. This immune therapy can cause a variety of ra...

29 June 2022 in Skin Health and Disease
Verified
Journal Article
Open access
PFPaula Finnegan
Paula Finnegan
LKLisa Kiely
Lisa Kiely
CGCatriona Gallagher
Catriona Gallagher
SMSarah Ni Mhaolcatha
Sarah Ni Mhaolcatha
LFLinda Feeley
Linda Feeley
LMLesley Ann Murphy
Lesley Ann Murphy
Radiation-induced morphea (RIM) is a rare but recognized late complication of radiotherapy. It was first described in 1905, not long after the initial discovery of X-rays by Roentgen. Characterized by the deposition of excess collagen in the dermis, it results in thickening of the skin. Its frequency is approximately 2 in 1000. We present a series of three cases involving patients receiving radiotherapy treatment for breast cancer, each of which subsequently developed RIM. Because of its rarity, RIM is often misdiagnosed as infection or metastatic disease. This can lead to delayed diagnosis and treatment, leading to poorer outcomes such as chronic pain issues. Early dermatological involvement and tissue sampling to examine histopathological features can avoid this, leading to better care and improved results. A variety of treatment options are available, ranging from topical to systemic, with early induction more likely to result in a positive response.

17 July 2023 in JAAD Case Reports
Verified
Journal Article
Open access
PFPaula Finnegan
Paula Finnegan
KAKashif Ahmad
Kashif Ahmad
MSMuriel Sadlier
Muriel Sadlier
MLMaeve Lynch
Maeve Lynch

22 March 2024 in JAAD Case Reports
Verified
Journal Article
Open access
PFPaula Finnegan
Paula Finnegan
MMMichelle Murphy
Michelle Murphy
JBJohn Bourke
John Bourke

20 October 2022 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PFPaula Finnegan
Paula Finnegan
MMMichelle Murphy
Michelle Murphy
COCathal O'COnnor
Cathal O'COnnor